Amends existing law to revise provisions regarding controlled substances.

The Idaho Board of Pharmacy administers the regulatory provisions of the state's Uniform Controlled Substances Act. This bill mirrors the federal Drug Enforcement Administration (DEA) controlled substance scheduling decisions for 2022, including placing synthetic opioids in Schedule I, a substance to treat insomnia in Schedule IV and an anticonvulsant substance in Schedule V.